Yunfei Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yunfei Chen has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Lei Zhang
State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
30 shared publications - Feng Xue
State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
21 shared publications - Rongfeng Fu
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
19 shared publications - Huan Dong
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
16 shared publications Xinyue Dai
State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
16 shared publicationsRenchi Yang
State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
15 shared publications
Latest Publications
- 16 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3853-3861
Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial
- 16 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3853-3861
Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial
- 18 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1725-1734
External validation of the AAA + survival model in a large Chinese cohort with essential thrombocythaemia
Summary: Triple A Plus (AAA+) is a recently proposed survival prediction model for essential thrombocythaemia (ET) intended for settings in which next‐generation sequencing is unavailable. However, independent validation in non‐Western populations remains limited. A retrospective cohort of 995 consecutive patients diagnosed with ET at a single centre between 2001 and 2022 was screened. Primary external validation was performed in 850 patients who had complete baseline variables required for the original AAA+ calculation. In the external‐validation cohort ( n = 850; deaths = 116), AAA+ demonstrated strong discrimination for overall survival ( C ‐index 0.892, 95% confidence interval 0.866–0.917). Time‐dependent analyses indicated superior discrimination across follow‐up, with 5‐ and 10‐year area under the curve values of 0.902 and 0.912, respectively, exceeding those of AAA (0.873 and 0.894) and International Prognostic Score for Essential Thrombocythemia (0.759 and 0.857). For 10‐year all‐cause mortality, decision‐curve analysis based on locally recalibrated absolute risks showed that AAA+ provided favourable net benefit across most clinically relevant thresholds. Diagnostic period‐adjusted analyses showed higher hazards of death in intermediate‐ and high‐risk patients than in low‐risk patients, with no clear evidence of temporal heterogeneity or monotonic attenuation of the AAA+ risk gradient over time. AAA+ exhibited robust risk stratification and good discrimination for overall survival in this large Chinese ET cohort.
- 18 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1725-1734
External validation of the AAA + survival model in a large Chinese cohort with essential thrombocythaemia
Summary: Triple A Plus (AAA+) is a recently proposed survival prediction model for essential thrombocythaemia (ET) intended for settings in which next‐generation sequencing is unavailable. However, independent validation in non‐Western populations remains limited. A retrospective cohort of 995 consecutive patients diagnosed with ET at a single centre between 2001 and 2022 was screened. Primary external validation was performed in 850 patients who had complete baseline variables required for the original AAA+ calculation. In the external‐validation cohort ( n = 850; deaths = 116), AAA+ demonstrated strong discrimination for overall survival ( C ‐index 0.892, 95% confidence interval 0.866–0.917). Time‐dependent analyses indicated superior discrimination across follow‐up, with 5‐ and 10‐year area under the curve values of 0.902 and 0.912, respectively, exceeding those of AAA (0.873 and 0.894) and International Prognostic Score for Essential Thrombocythemia (0.759 and 0.857). For 10‐year all‐cause mortality, decision‐curve analysis based on locally recalibrated absolute risks showed that AAA+ provided favourable net benefit across most clinically relevant thresholds. Diagnostic period‐adjusted analyses showed higher hazards of death in intermediate‐ and high‐risk patients than in low‐risk patients, with no clear evidence of temporal heterogeneity or monotonic attenuation of the AAA+ risk gradient over time. AAA+ exhibited robust risk stratification and good discrimination for overall survival in this large Chinese ET cohort.
- 30 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (3) , 1280-1290
Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events
Summary: Congenital factor XII (FXII) deficiency is a rare disorder resulting from F12 gene mutations and its precise contribution to thrombotic or haemorrhagic risk has yet to be established. We identified the same mutation of the F12 gene across five pedigrees, yet the clinical manifestations varied markedly, ranging from asymptomatic to thrombotic and haemorrhagic phenotypes. Haematological assessments and deoxyribonucleic acid sequencing were conducted in five pedigrees. All five probands displayed prolonged activated partial thromboplastin time, markedly reduced FXII activity and an identical frameshift mutation in F12 (c.303_304delCA, p.H101Qfs*36), leading to the loss of functional domains. In Pedigree A, characterized by thrombotic clustering, thrombotic events were documented in 4 of 6 mutation carriers and 4 of 13 non‐carriers. In Pedigree B, the proband experienced bleeding events, and her father died of intracerebral haemorrhage. Probands C and D remained asymptomatic. Proband E was diagnosed with essential thrombocythaemia and thrombosis. Across all pedigrees, haemorrhagic or thrombotic events could be attributed to additional contributing factors. The identified apolipoprotein E and butyrophilin subfamily 2 member A1 variants were consistently associated with thrombotic events in Pedigree A. This F12 variant does not appear to independently drive pathological coagulation phenotypes but may potentiate susceptibility to thrombosis in the presence of additional genetic or acquired risk factors.
- 30 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (3) , 1280-1290
Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events
Summary: Congenital factor XII (FXII) deficiency is a rare disorder resulting from F12 gene mutations and its precise contribution to thrombotic or haemorrhagic risk has yet to be established. We identified the same mutation of the F12 gene across five pedigrees, yet the clinical manifestations varied markedly, ranging from asymptomatic to thrombotic and haemorrhagic phenotypes. Haematological assessments and deoxyribonucleic acid sequencing were conducted in five pedigrees. All five probands displayed prolonged activated partial thromboplastin time, markedly reduced FXII activity and an identical frameshift mutation in F12 (c.303_304delCA, p.H101Qfs*36), leading to the loss of functional domains. In Pedigree A, characterized by thrombotic clustering, thrombotic events were documented in 4 of 6 mutation carriers and 4 of 13 non‐carriers. In Pedigree B, the proband experienced bleeding events, and her father died of intracerebral haemorrhage. Probands C and D remained asymptomatic. Proband E was diagnosed with essential thrombocythaemia and thrombosis. Across all pedigrees, haemorrhagic or thrombotic events could be attributed to additional contributing factors. The identified apolipoprotein E and butyrophilin subfamily 2 member A1 variants were consistently associated with thrombotic events in Pedigree A. This F12 variant does not appear to independently drive pathological coagulation phenotypes but may potentiate susceptibility to thrombosis in the presence of additional genetic or acquired risk factors.
- 29 April 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (6) , 2026-2036
Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial
Autoimmunity remains challenging to treat without broad immunosuppression. We previously showed that anti-CD38 antibody can rapidly elevate platelet counts in refractory immune thrombocytopenia (ITP), but the underlying mechanism was unclear. Here we report that anti-CD38 antibody induces platelet recovery within 3 days, including after retreatment in relapsed cases. Mechanistically, CD38-mediated nicotinamide adenine dinucleotide (NAD+) depletion drives M1-like macrophage polarization with increased Fc gamma receptor I (FcγRI) expression, thereby promoting macrophage phagocytosis of opsonized platelets. In mice, CD38 inhibition or nicotinamide mononucleotide (NMN) supplementation restores NAD+, reprograms macrophages, downregulates FcγRI and prevents thrombocytopenia. In an ovalbumin immunization model, NMN treatment does not impair antigen-specific antibody production, supporting preservation of humoral responses. Based on these findings, we conducted a single-arm, open-label phase 1/2 trial of low-dose oral NMN (450 mg twice daily for 2 weeks) in adults with steroid-refractory or steroid-dependent ITP. Primary endpoints were safety/tolerability and platelet response (≥50 × 109 per liter within 2 weeks, confirmed by two consecutive measurements one or more days apart, without rescue therapy or dose escalation of thrombopoietin receptor agonists or corticosteroids). Among 25 enrolled patients, no dose-limiting toxicities or treatment-related serious adverse events occurred; NMN was well tolerated, with only mild treatment-related adverse events in 12% and non-severe infections (grade 1) in 8% of patients while immunoglobulin levels remained stable, consistent with preserved humoral immunity. Five patients (20.0%) met the primary platelet-response endpoint. In exploratory analyses, overall, 60% of patients achieved platelet counts more than 1.5× baseline during treatment, and 52% maintained responses through week 8. Together, these data identify the CD38−NAD+ axis as an immunometabolic checkpoint in ITP and support further exploration of NMN as a non-antibody-depleting metabolic strategy for antibody-mediated disease. ClinicalTrials.gov identifier: NCT06776510.
- 29 April 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (6) , 2026-2036
Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial
Autoimmunity remains challenging to treat without broad immunosuppression. We previously showed that anti-CD38 antibody can rapidly elevate platelet counts in refractory immune thrombocytopenia (ITP), but the underlying mechanism was unclear. Here we report that anti-CD38 antibody induces platelet recovery within 3 days, including after retreatment in relapsed cases. Mechanistically, CD38-mediated nicotinamide adenine dinucleotide (NAD+) depletion drives M1-like macrophage polarization with increased Fc gamma receptor I (FcγRI) expression, thereby promoting macrophage phagocytosis of opsonized platelets. In mice, CD38 inhibition or nicotinamide mononucleotide (NMN) supplementation restores NAD+, reprograms macrophages, downregulates FcγRI and prevents thrombocytopenia. In an ovalbumin immunization model, NMN treatment does not impair antigen-specific antibody production, supporting preservation of humoral responses. Based on these findings, we conducted a single-arm, open-label phase 1/2 trial of low-dose oral NMN (450 mg twice daily for 2 weeks) in adults with steroid-refractory or steroid-dependent ITP. Primary endpoints were safety/tolerability and platelet response (≥50 × 109 per liter within 2 weeks, confirmed by two consecutive measurements one or more days apart, without rescue therapy or dose escalation of thrombopoietin receptor agonists or corticosteroids). Among 25 enrolled patients, no dose-limiting toxicities or treatment-related serious adverse events occurred; NMN was well tolerated, with only mild treatment-related adverse events in 12% and non-severe infections (grade 1) in 8% of patients while immunoglobulin levels remained stable, consistent with preserved humoral immunity. Five patients (20.0%) met the primary platelet-response endpoint. In exploratory analyses, overall, 60% of patients achieved platelet counts more than 1.5× baseline during treatment, and 52% maintained responses through week 8. Together, these data identify the CD38−NAD+ axis as an immunometabolic checkpoint in ITP and support further exploration of NMN as a non-antibody-depleting metabolic strategy for antibody-mediated disease. ClinicalTrials.gov identifier: NCT06776510.
- Open Access
- 12 March 2026
- Published by Elsevier in Blood Reviews
- Vol. 76, 101387
Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies
- 12 March 2026
- Published by Elsevier in Blood Reviews
- Vol. 76, 101387
Open AccessTowards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies
- Open Access
- 11 March 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 88
Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity
This prospective phase 1 pilot study evaluated the safety and efficacy of GS001, an adeno-associated virus serotype 8 (AAV8)-based vector encoding B-domain–deleted factor VIII with exploratory assessment of prophylactic immunosuppression. Twelve adult severe hemophilia A participants were enrolled. Participants received GS001 at either 2×10¹² (low dose cohort) or 4×10¹² (high dose cohort) vg/kg following prophylactic treatment with prednisone alone or prednisone plus tacrolimus starting from one week before GS001 infusion. Median (range) follow-up was 156.0 (144.0-208.0) / 110.5 (104.0-130.0) weeks (2×10¹² / 4×10¹² vg/kg). Transgene expression peaked at 5-7 weeks post-infusion. In low dose cohort, at week 144.0, median (range) factor VIII activity was 5.6 (0.5-52.0) IU/dL (n = 6). In high dose cohort, at week 104.0, median (range) factor VIII activity was 42.7 (29.4-92.1) IU/dL (n = 6) and all six participants sustained factor VIII levels above 29 IU/dL. Both cohorts showed significant reductions in annualized bleeding rate and factor VIII consumption with grade 1-2 adverse events. Alanine aminotransferase elevations occurred in 3/6 and 5/6 low/high-dose participants and most were grade 1. The Single-cell RNA analysis demonstrated that the prednisone plus tacrolimus pretreatment effectively inhibited CD8+ T cell immune responses in both cohorts. Overall, GS001 infusion was safe and well-tolerated, achieving a significant increase in factor VIII level. Pre-treatment with glucocorticoids and tacrolimus may benefit by suppressing induced immune responses, thereby enhancing transgene expression without increasing the risk of infection. This study was registered at www.clinicaltrials.gov as # NCT04728841.
- 11 March 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 88
Open AccessPhase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity
This prospective phase 1 pilot study evaluated the safety and efficacy of GS001, an adeno-associated virus serotype 8 (AAV8)-based vector encoding B-domain–deleted factor VIII with exploratory assessment of prophylactic immunosuppression. Twelve adult severe hemophilia A participants were enrolled. Participants received GS001 at either 2×10¹² (low dose cohort) or 4×10¹² (high dose cohort) vg/kg following prophylactic treatment with prednisone alone or prednisone plus tacrolimus starting from one week before GS001 infusion. Median (range) follow-up was 156.0 (144.0-208.0) / 110.5 (104.0-130.0) weeks (2×10¹² / 4×10¹² vg/kg). Transgene expression peaked at 5-7 weeks post-infusion. In low dose cohort, at week 144.0, median (range) factor VIII activity was 5.6 (0.5-52.0) IU/dL (n = 6). In high dose cohort, at week 104.0, median (range) factor VIII activity was 42.7 (29.4-92.1) IU/dL (n = 6) and all six participants sustained factor VIII levels above 29 IU/dL. Both cohorts showed significant reductions in annualized bleeding rate and factor VIII consumption with grade 1-2 adverse events. Alanine aminotransferase elevations occurred in 3/6 and 5/6 low/high-dose participants and most were grade 1. The Single-cell RNA analysis demonstrated that the prednisone plus tacrolimus pretreatment effectively inhibited CD8+ T cell immune responses in both cohorts. Overall, GS001 infusion was safe and well-tolerated, achieving a significant increase in factor VIII level. Pre-treatment with glucocorticoids and tacrolimus may benefit by suppressing induced immune responses, thereby enhancing transgene expression without increasing the risk of infection. This study was registered at www.clinicaltrials.gov as # NCT04728841.
- 29 January 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (4) , 1346-1358
Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura
- 29 January 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (4) , 1346-1358
Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura
- Open Access
Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial
Objective: To assess the efficacy and safety of CM313, an anti-CD38 monoclonal antibody, in adults with persistent or chronic primary immune thrombocytopenia. Design: Multicentre, randomised, placebo controlled, phase 2 trial. Setting: Five hospitals in China, 16 January to 11 June 2024. Participants: 45 patients aged ≥18 years with persistent or chronic immune thrombocytopenia who failed to respond to, or relapsed after, glucocorticoid treatment but had previously responded to standard first line treatment. Interventions: Patients were randomised to receive intravenous CM313 (16 mg/kg) or placebo weekly for eight weeks. Main outcome measures: The primary outcome was overall response rate (at least two consecutive platelet counts ≥30×10 9 /L, a minimum doubling from baseline, and no bleeding) at week 8. A secondary outcome was time to the first two consecutive platelet counts ≥50×10 9 /L. Results: Of 56 patients screened, 45 were randomised to receive CM313 (n=30) or placebo (n=15). At week 8, the overall response rate was higher in the CM313 group (83%; 25/30) compared with placebo group (20%; 3/15): difference 63.3% (95% confidence interval 33.7% to 81.3%; P9 /L was one week in the CM313 group but was not reached in the placebo group (P9 /L was 18 weeks in the CM313 group versus three weeks in the placebo group (P=0.004). Treatment emergent adverse events occurred in 87% (26/30) of patients in the CM313 group and 80% (12/15) in the placebo group, with infusion related reactions and petechiae being the most common. Conclusion: CM313 showed a favourable safety profile and encouraging efficacy in adults with persistent or chronic primary immune thrombocytopenia, characterised by rapid increase in platelet count, sustained platelet responses, and manageable adverse events. Trial registration: ClinicalTrials.gov NCT06199089 .
Open AccessAnti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial
Objective: To assess the efficacy and safety of CM313, an anti-CD38 monoclonal antibody, in adults with persistent or chronic primary immune thrombocytopenia. Design: Multicentre, randomised, placebo controlled, phase 2 trial. Setting: Five hospitals in China, 16 January to 11 June 2024. Participants: 45 patients aged ≥18 years with persistent or chronic immune thrombocytopenia who failed to respond to, or relapsed after, glucocorticoid treatment but had previously responded to standard first line treatment. Interventions: Patients were randomised to receive intravenous CM313 (16 mg/kg) or placebo weekly for eight weeks. Main outcome measures: The primary outcome was overall response rate (at least two consecutive platelet counts ≥30×10 9 /L, a minimum doubling from baseline, and no bleeding) at week 8. A secondary outcome was time to the first two consecutive platelet counts ≥50×10 9 /L. Results: Of 56 patients screened, 45 were randomised to receive CM313 (n=30) or placebo (n=15). At week 8, the overall response rate was higher in the CM313 group (83%; 25/30) compared with placebo group (20%; 3/15): difference 63.3% (95% confidence interval 33.7% to 81.3%; P9 /L was one week in the CM313 group but was not reached in the placebo group (P9 /L was 18 weeks in the CM313 group versus three weeks in the placebo group (P=0.004). Treatment emergent adverse events occurred in 87% (26/30) of patients in the CM313 group and 80% (12/15) in the placebo group, with infusion related reactions and petechiae being the most common. Conclusion: CM313 showed a favourable safety profile and encouraging efficacy in adults with persistent or chronic primary immune thrombocytopenia, characterised by rapid increase in platelet count, sustained platelet responses, and manageable adverse events. Trial registration: ClinicalTrials.gov NCT06199089 .
- Open Access
- 23 July 2025
- Published by Springer Nature in Research Square
A Proteomics-Driven Machine Learning Tool for Distinguishing ET from pre-PMF
Essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) are phenotypically similar but biologically distinct myeloproliferative neoplasms (MPNs), making accurate diagnosis critical yet challenging. We conducted a retrospective study, including 434 ET and 91 pre-PMF patients. Clinical predictors were evaluated using logistic regression in 440 patients. A subset of 85 patients underwent data-independent acquisition (DIA)–based proteomic profiling of FFPE bone marrow samples. Diagnostic models were developed using clinical, proteomic, and combined features, with performance assessed via nested cross-validation. A 9-protein classifier was constructed using random forest followed by support vector machine–recursive feature elimination (SVM-RFE). The proteomic model achieved superior diagnostic performance compared to the clinical model (AUC = 0.849 vs. 0.499) and was comparable to the combined model (AUC = 0.845). The 9-protein panel showed robust discrimination (AUC = 0.895), with top proteins (ARHGEF19, CAST, SFTPA2) performing well in JAK2V617F⁺ (AUC = 0.971) and CALR⁺ (AUC = 0.768) subsets. Proteomic profiling thus outperforms conventional clinical variables and offers a reproducible, molecular-based tool for distinguishing ET from pre-PMF, with potential utility across molecular subtypes in early-phase MPN diagnosis.
- 23 July 2025
- Published by Springer Nature in Research Square
Open AccessA Proteomics-Driven Machine Learning Tool for Distinguishing ET from pre-PMF
Essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) are phenotypically similar but biologically distinct myeloproliferative neoplasms (MPNs), making accurate diagnosis critical yet challenging. We conducted a retrospective study, including 434 ET and 91 pre-PMF patients. Clinical predictors were evaluated using logistic regression in 440 patients. A subset of 85 patients underwent data-independent acquisition (DIA)–based proteomic profiling of FFPE bone marrow samples. Diagnostic models were developed using clinical, proteomic, and combined features, with performance assessed via nested cross-validation. A 9-protein classifier was constructed using random forest followed by support vector machine–recursive feature elimination (SVM-RFE). The proteomic model achieved superior diagnostic performance compared to the clinical model (AUC = 0.849 vs. 0.499) and was comparable to the combined model (AUC = 0.845). The 9-protein panel showed robust discrimination (AUC = 0.895), with top proteins (ARHGEF19, CAST, SFTPA2) performing well in JAK2V617F⁺ (AUC = 0.971) and CALR⁺ (AUC = 0.768) subsets. Proteomic profiling thus outperforms conventional clinical variables and offers a reproducible, molecular-based tool for distinguishing ET from pre-PMF, with potential utility across molecular subtypes in early-phase MPN diagnosis.
- 29 May 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (20) , 2069-2071
Daratumumab in Relapsed or Refractory Pediatric Immune Thrombocytopenia
- 29 May 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (20) , 2069-2071
Daratumumab in Relapsed or Refractory Pediatric Immune Thrombocytopenia